Aschner Pablo, Galstyan Gagik, Yavuz Dilek G, Litwak Leon, Gonzalez-Galvez Guillermo, Goldberg-Eliaschewitz Freddy, Hafidh Khadija, Djaballah Khier, Tu Shih-Te, Unnikrishnan Ambika G, Khunti Kamlesh
Javeriana University School of Medicine and San Ignacio University Hospital, Bogota, Colombia.
Endocrinology Research Center, Moscow, Russia.
Diabetes Ther. 2021 May;12(5):1491-1501. doi: 10.1007/s13300-021-00997-0. Epub 2021 Apr 10.
Trends on glycemic control and diabetes complications are known for high-income countries, but comprehensive data from low- and middle-income countries (LMIC) are lacking.
This is an expert opinion based on two retrospective studies. Here we examine the recent subset analysis of relevant data from the IDMPS Wave 7 (International Diabetes Management-Practices Study, 2015-2016) and the GOAL study conducted in multiple LMICs.
Wave 7 sub-analysis was performed in 6113 people with type 2 diabetes from 24 LMIC. Poorly controlled diabetes (hemogloblin A1c [HbA1c] ≥ 7%) was found in 58.6, 73.0 and 78.3% of participants with diabetes duration of < 5, 5-12 and > 12 years, respectively (in association with a high prevalence of macro- and microvascular complications). Moreover, 37.7% of participants with diabetes duration of 5-12 years were treated only with oral antihyperglycemic drugs. The GOAL study investigated the efficacy of insulin in 2704 poorly controlled participants (mean HbA1c 9.7%; diabetes duration 10.1 ± 6.7 years; 10 LMIC). A significant 2% reduction in mean HbA1c levels was observed after 12 months of treatment. Only 7.2% of participants experienced a symptomatic episode of hypoglycemia (nocturnal or severe hypoglycemia events were infrequent).
The rate of well-controlled participants (HbA1c < 7.0%) in the Wave 7 sub-analysis was lower than that observed in the USA (NHANES survey) or in European countries (GUIDANCE study), and the incidence of microvascular complications was higher. The GOAL study showed that insulin treatment improves glycemic control and reduces this gap. The Expert Panel recommends intensifying diabetes treatment as soon as possible, as well as patients' education and other preventive measures, initiatives which require modest costs compared to hospitalization and treatment of diabetes complications.
高收入国家的血糖控制和糖尿病并发症趋势已为人所知,但低收入和中等收入国家(LMIC)缺乏全面的数据。
这是基于两项回顾性研究得出的专家意见。在此,我们研究了IDMPS第7波(国际糖尿病管理实践研究,2015 - 2016年)和在多个低收入和中等收入国家开展的GOAL研究中相关数据的近期亚组分析。
对来自24个低收入和中等收入国家的6113例2型糖尿病患者进行了第7波亚组分析。糖尿病病程<5年、5 - 12年和>12年的参与者中,血糖控制不佳(糖化血红蛋白[HbA1c]≥7%)的比例分别为58.6%、73.0%和78.3%(伴有高比例的大血管和微血管并发症)。此外,糖尿病病程为5 - 12年的参与者中,37.7%仅接受口服降糖药治疗。GOAL研究在2704例血糖控制不佳的参与者(平均HbA1c 9.7%;糖尿病病程10.1±6.7年;10个低收入和中等收入国家)中研究了胰岛素的疗效。治疗12个月后,平均HbA1c水平显著降低了2%。只有7.2%的参与者经历了有症状的低血糖发作(夜间或严重低血糖事件很少见)。
第7波亚组分析中血糖控制良好(HbA1c<7.0%)的参与者比例低于美国(NHANES调查)或欧洲国家(GUIDANCE研究),微血管并发症的发生率更高。GOAL研究表明胰岛素治疗可改善血糖控制并缩小这一差距。专家小组建议尽快加强糖尿病治疗以及患者教育和其他预防措施,与糖尿病并发症的住院治疗相比,这些举措成本较低。